4 completed, 3 recruiting, 2 terminated, 1 active not recruiting. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 4, Recruiting 3, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow CHOP: new trials by email Literature Review of CHOP trials Research Report on CHOP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma Linperlisib - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai YingLi Pharmaceutical Co. Ltd. | 606 | 2024-09-10 | 2024-08-12 |
| Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Etoposide, Cytarabine, PEG-rhG-CSF - Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2025-12-04 |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Belinostat Injection, Pralatrexate Injection, CHOP - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | Acrotech Biopharma Inc. | 504 | 2023-10-04 | 2026-10-15 |
| Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma Mosunetuzumab (SC), Rituximab (R), Bendamustine - Marginal Zone Lymphoma | Phase 3 | Recruiting | The Lymphoma Academic Research Organisation | 260 | 2023-09-05 | 2026-06-15 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | MEI Pharma, Inc. | 82 | 2021-08-13 | 2024-11-04 |
| PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy CHOP, CHOP Plus Lanzoprazole, CHOP Plus Famotidine - Lymphoma | Phase 3 | Recruiting | Sherief Abd-Elsalam | 60 | 2018-08-01 | 2018-08-27 |
| Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL HLX01, Rituximab, CHOP - B-cell Non Hodgkin's Lymphoma | Phase 3 | Completed | Shanghai Henlius Biotech | 407 | 2015-10-01 | 2022-05-09 |
| Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Romidepsin + CHOP, CHOP - Peripheral T-cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 421 | 2013-01-01 | 2023-01-10 |
| A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma CHOP, rituximab [MabThera/Rituxan] - Lymphoma, Large B-Cell, Diffuse | Phase 3 | Completed | Hoffmann-La Roche | 572 | 2012-08-24 | 2017-10-11 |
| Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL CEOP regimen, CHOP regimen - Lymphoma | Phase 3 | Completed | Fudan University | 398 | 2009-03-01 | 2014-08-20 |
| A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients chemotherapy (CHOP), chemotherapy(c-ATT) - T-cell Lymphoma Adults, Previously Untreated | Phase 3 | Unknown | Sun Yat-sen University | 380 | 2008-01-01 | 2015-12-11 |
| A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma Bevacizumab, Rituximab, CHOP - B-cell Lymphoma | Phase 3 | Terminated | Hoffmann-La Roche | 787 | 2007-07-26 | 2017-07-25 |
Lymphoma, B-Cell (3) · Lymphoma, T-Cell, Peripheral (3) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Non-Hodgkin (2) · Cardiotoxicity (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
Hoffmann-La Roche (2) · The Lymphoma Academic Research Organisation (2) · Acrotech Biopharma Inc. (1) · Fudan University (1) · MEI Pharma, Inc. (1) · Shanghai Henlius Biotech (1) · Shanghai YingLi Pharmaceutical Co. Ltd. (1) · Sherief Abd-Elsalam (1) · Sun Yat-sen University (1) · The Affiliated People's Hospital of Ningbo University (1)
Italy (6) · China (5) · France (5) · Spain (5) · Belgium (4) · Canada (4) · Germany (4) · Poland (4) · Portugal (4) · South Korea (4) · Greece (3) · Hungary (3) · Taiwan (3) · Turkey (Türkiye) (3) · United Kingdom (3)
Guan ZhongZhen (1) · Peipei Ye (1) · Sahar K Hegazy, Prof (1) · Sahar M El-Haggar, prof (1) · Suzan A Alhassanin, Ph D (1) · Uma Srinivas Atmuri, MPharm, MS (1) · Ye Guo, MD (1)
PMID 24895339, PMID 28935843, PMID 30770362, PMID 32299513, PMID 33394214, PMID 34843406, PMID 38364196, PMID 42699559